Pelage Pharmaceutical raised $14M in a Series A-1 funding led by GV to accelerate its Phase 2 clinical program for hair loss treatments.

Aug 13, 2024•12 months ago

Amount Raised

$14 Million

Los AngelesBiotechnologyHealthcare

Investors

Description

Pelage Pharmaceutical, a clinical-stage regenerative medicine company, raised $14M in Series A-1 funding. The funds will be used to speed up its Phase 2 clinical program for treating hair loss, specifically targeting androgenetic alopecia and chemotherapy-induced alopecia.

Company Information

Company

Pelage Pharmaceuticals

Location

Los Angeles, California, United States

About

At Pelage Pharmaceuticals, our goal is to deliver a scientifically based, clinically tested treatment for both men and women battling the emotional pain or social stigma of hair loss. Based on the breakthrough innovation by Pelage Pharmaceuticals co-founders, we stimulate hair growth by targeting the metabolism of hair follicle stem cells in most forms of alopecia.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends